Attenuation of radiation- and chemoradiation-induced mucositis using gamma-d-glutamyl-l-tryptophan (SCV-07)
Article first published online: 19 APR 2010
© 2010 John Wiley & Sons A/S
Volume 16, Issue 7, pages 655–660, October 2010
How to Cite
Watkins, B., Pouliot, K., Fey, E., Tuthill, C. and Sonis, S. (2010), Attenuation of radiation- and chemoradiation-induced mucositis using gamma-d-glutamyl-l-tryptophan (SCV-07). Oral Diseases, 16: 655–660. doi: 10.1111/j.1601-0825.2010.01671.x
- Issue published online: 15 SEP 2010
- Article first published online: 19 APR 2010
- Received 19 October 2009; accepted 13 November 2009
- animal models
Oral Diseases (2010) 16, 655–660
Objective: To evaluate the efficacy of a novel immunomodulating peptide (SCV-07) in attenuating the course of radiation-induced mucositis in an established animal model of oral mucositis (OM).
Material and Methods: In three separate experiments, golden Syrian hamsters received either an acute radiation challenge to the buccal mucosa of eight fractionated doses of 7.5 Gy of radiation over a 2-week-period, or a combination of acute radiation and cisplatin. In each experiment, animals were treated with varying doses or schedules of SCV-07 or placebo. OM was scored in a blinded fashion using digital images obtained during the experimental period.
Results: We found that SCV-07 reduced the severity and duration of both acute and fractionated radiation-induced OM. Similarly, when radiation and chemotherapy were used to induce OM, treatment with SCV-07 significantly reduced the duration of ulcerative OM. The therapeutic benefit was dependent on both dose and schedule of administration.
Conclusion: Taken together, we found SCV-07 was able to modify the duration and severity of oral mucositis and was dependent on schedule and dose.